Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01041105 · ClinicalTrials.gov registry record

Gastric Bypass After Previous Anti-reflux Surgery

A clinical trial of Gastroesophageal Reflux Disease and Clinically Severe Obesity, sponsored by University of California, San Francisco.

Completed
Registry status
22
Enrollment target
1
Study location

NCT01041105: Completed study of Gastroesophageal Reflux Disease and Clinically Severe Obesity, sponsored by University of California, San Francisco.

NCT01041105 is a study of Gastroesophageal Reflux Disease and Clinically Severe Obesity that has completed, run by University of California, San Francisco. The registered enrollment target is 22 participants, below the 355-participant average among 25 other Gastroesophageal Reflux Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01041105, a study of Gastroesophageal Reflux Disease and Clinically Severe Obesity, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
22 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to describe the clinical presentation, indications, and operative treatment as well as assess the morbidity, mortality, and overall performance of revisional Roux-en-Y gastric bypass (RYGB) after either failed or functional antireflux surgery "ARS" in obese patients. With such information, we hope to determine which features might assist us in advancing our knowledge about Gastro-Esophageal Reflux Disease "GERD", the best option for primary ARS, and mechanisms of failure in the obese population as well as in identifying predictors of outcome after revisional surgery in this population.

Study Locations (1)

California

  • UCSF Fresno Center for Medical Education and Research - Fresno

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2008-12
Est. Completion 2009-12

What the finished NCT01041105 record still lists

NCT01041105 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 355-participant average among 25 other Gastroesophageal Reflux Disease trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01041105 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01041105 about?

NCT01041105 is a clinical study titled "Gastric Bypass After Previous Anti-reflux Surgery". The goal of this study is to describe the clinical presentation, indications, and operative treatment as well as assess the morbidity, mortality, and overall performance of revisional Roux-en-Y gastric bypass (RYGB) after either failed or functional antireflux surgery "ARS" in obese patients. With s...

What is the current status of trial NCT01041105?

This trial is currently completed. The enrollment target is 22 participants. The study started on 2008-12. Estimated completion is 2009-12.

What conditions does trial NCT01041105 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux Disease, Clinically Severe Obesity.

Who is sponsoring clinical trial NCT01041105?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01041105 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroesophageal Reflux Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01041105's enrollment target sits among peer trials

22 24th of 25 higher than 2 of 25 other Gastroesophageal Reflux Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroesophageal Reflux Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01041105, the US trial registry maintained by the National Library of Medicine. NCT01041105 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.